If there already kidney function decline in Polycystic Kidney Disease
patients, Immunotherapy will be recommended therapy. If analyzed from cytology,
there are three types of cells in your kidneys when the kidneys are damaged by
PKD. There are healthy functional cells, damaged cells and necrotic cells.
Healthy cells are working excessively, and if checked by Biopsy, we can find
these cells are enlarged. Long term overloaded station makes them fragile to any
external influence like infection. And this is the reason why some PKD patient
with stable condition may experience sharp kidney function decline after an
infection like serious cold.
As to these damaged cells, they are still working but partial incapability,
and they are on the road of becoming necrotic. As to these necrotic cells,
frankly speaking, there is no method to restore their function. Treatment for
kidney failure should be a holistic treatment that alleviates internal influence
to provide a favorable environment for the recuperation and self-repairing of
these overloaded and damaged cells, and the treatment for PKD patients should
also replenish the absolute number of functioning kidney cells.
As mentioned before, necrosis is an absolute loss of overall kidney function.
And this is because that kidney differs from other organs like the Liver in that
once there is renal cell necrosis, the kidneys are incapable of regenerating
more cells to replace these died ones. And, this is also why kidney failure is
considered as irreversible.
However, Immunotherapy can differentiate into kidney cells. Immunotherapy are
original cells with multi-potential and multi-directional differentiation
ability, which means that, after cultivation, Immunotherapy can differentiate
into functional cells of one specific organ, like the kidney.
We take advantage of this very characteristic of Immunotherapy in treating
kidney function decline. Umbilical Mesenchymal Immunotherapy and Cord Blood
Immunotherapy are adopted in our hospital, and they mainly differentiate into
kidney parenchymal cells and kidney blood capillary cells separately, which will
take place of the dead cells and tissues, improving the kidney functions in
patients with PKD.
Immunotherapy are provided and cultivated by the hospital, and transfused
into patient’s body through intravenous drip. So, no surgical operation is
needed.
In summary, this treatment is a conservative treatment method, and aims at
protecting and restoring overall kidney function to a more satisfying level to
prolong or avoid the necessity of dialysis or kidney
transplant for patients with PKD.
